Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL

NCT06573138 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma, Extranodal NK-T-Cell

Interventions

DRUG: Selinexor, anti-PD-1 antibody plus Golidocitinib

Sponsor

Ruijin Hospital